Pantelis Panagakis

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 05, 2026

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Long-Term Outcomes of Guselkumab and Risankizumab for the Management of Moderate-to-Severe Psoriasis in the Elderly: Results from a Real-World Retrospective Study.

Journal: Journal of clinical medicine

Published: July 25, 2025

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.

Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.

Journal: Dermatology and therapy

Published: July 10, 2025

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Journal: Clinical and experimental dermatology

Published: May 12, 2025

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission.

Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission.

Journal: Frontiers in medicine

Published: February 25, 2025

Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Journal: International journal of dermatology

Published: November 21, 2024

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

Journal: Archives of dermatological research

Published: July 20, 2024

Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.

Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.

Journal: International journal of dermatology

Published: April 09, 2024

Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.

Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.

Journal: Archives of dermatological research

Published: March 21, 2024

Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.

Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 26, 2023

Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).

Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 27, 2023

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review.

The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review.

Journal: Biomedicines

Published: December 28, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026